AbbVie's venetoclax made available on UK's early access scheme for CLL

23 August 2016
2019_biotech_test_vial_discovery_big

US drugmaker AbbVie (NYSE: ABBV) has received a positive scientific opinion through the UK’s Early Access to Medicines Scheme (EAMS) for venetoclax, a treatment for chronic lymphocytic leukemia (CLL).

Venetoclax, which was granted this status from the Medicines and Healthcare products Regulatory Agency, is now potentially available to patients with certain types of difficult-to-treat CLL while the marketing authorization application is under review by the European Medicines Agency.

An investigational therapy with trials in relapsed or refractory CLL, an area of high unmet need, venetoclax is AbbVie’s first oncology therapy in the UK and the first treatment for CLL to be made available through EAMS.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology